PMID: 9449287Feb 4, 1998Paper

Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia

Antimicrobial Agents and Chemotherapy
P M Roblin, M R Hammerschlag

Abstract

Chlamydia pneumoniae was eradicated from the nasopharynges of 26 of 33 (78.8%) evaluable children and adults with community-acquired pneumonia who were treated with azithromycin. We tested 55 isolates of C. pneumoniae obtained from 46 of these patients against azithromycin. The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of strains tested were killed of azithromycin for these isolates were both 0.5 microg/ml. Seven patients remained culture positive after treatment. The MICs of azithromycin for isolates from two patients increased fourfold after therapy. However, all the patients with persistent infection improved clinically. Further studies of treatment of C. pneumoniae infection, utilizing culture, are needed both to assess efficacy and to monitor for the possible development of antibiotic resistance.

References

Jul 1, 1992·Antimicrobial Agents and Chemotherapy·M R HammerschlagP M Roblin
Aug 1, 1992·Journal of Clinical Microbiology·P M RoblinM R Hammerschlag
Jan 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M R HammerschlagJ Schachter
Oct 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S SchönwaldM Gunjaca
Apr 1, 1990·The Journal of Infectious Diseases·J T GraystonS P Wang
Dec 1, 1990·The Journal of Infectious Diseases·R B JonesM K Shepard
Nov 1, 1980·Antimicrobial Agents and Chemotherapy·A MouradJ Schachter
Jan 1, 1994·Scandinavian Journal of Infectious Diseases·S SchönwaldM Gunjaca
Jul 1, 1994·Antimicrobial Agents and Chemotherapy·P M RoblinM R Hammerschlag

❮ Previous
Next ❯

Citations

Aug 29, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M R Hammerschlag
Apr 17, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N PrincipiUNKNOWN Mowgli study group
Mar 7, 2003·Journal of Medical Microbiology·Naoyuki MiyashitaToshiharu Matsushima
Oct 16, 2004·Expert Review of Anti-infective Therapy·Margaret R Hammerschlag
Jan 13, 2010·Antimicrobial Agents and Chemotherapy·Rachel BinetRoger G Rank
Jul 1, 2010·Expert Review of Anti-infective Therapy·Frédéric Lamoth, Gilbert Greub
Jul 28, 2010·Antimicrobial Agents and Chemotherapy·Ronald N JonesMargaret R Hammerschlag
Feb 10, 2012·Expert Opinion on Pharmacotherapy·Margaret R Hammerschlag, Stephan A Kohlhoff
Jan 10, 2002·Clinical Microbiology Reviews·Jens Boman, Margaret R Hammerschlag
Mar 7, 2008·Expert Opinion on Investigational Drugs·Margaret R Hammerschlag, Roopali Sharma
Mar 15, 2005·Scandinavian Journal of Infectious Diseases·Eva BrandénGöran Tornling
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·Paul F RiskaMargaret R Hammerschlag
Apr 11, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·William L Baker, Kimberly A Couch
Sep 24, 2010·Future Microbiology·Kelsi M Sandoz, Daniel D Rockey
Jan 13, 2015·Expert Opinion on Pharmacotherapy·Stephan A Kohlhoff, Margaret R Hammerschlag
Dec 6, 2016·Microorganisms·Leena Hanski, Pia Vuorela
Jun 5, 2019·Antimicrobial Agents and Chemotherapy·Stephan KohlhoffMargaret R Hammerschlag
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·P J Cook
May 23, 2003·Antimicrobial Agents and Chemotherapy·Hiroyuki YamaguchiYoshimasa Yamamoto
Mar 14, 2008·Clinical Science·Caroline Watson, Nicholas J Alp
Sep 16, 2005·Journal of Computer Assisted Tomography·Fumito OkadaHiromu Mori
Nov 30, 2000·Current Infectious Disease Reports·M R Hammerschlag
Jan 29, 2005·Clinical Pediatrics·Stephen I Pelton, Margaret R Hammerschlag
May 17, 2002·Current Opinion in Infectious Diseases·Nicola Principi, Susanna Esposito
May 20, 2000·Antimicrobial Agents and Chemotherapy·M R Hammerschlag, P M Roblin
Dec 30, 2009·Antimicrobial Agents and Chemotherapy·Patricia M RoblinMargaret R Hammerschlag
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·Rachel Binet, Anthony T Maurelli
Oct 8, 2014·Antimicrobial Agents and Chemotherapy·Stephan A KohlhoffMargaret R Hammerschlag
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·Sheila MalayMargaret R Hammerschlag
Dec 20, 2002·Seminars in Pediatric Infectious Diseases·Margaret R Hammerschlag
Jun 22, 2021·Antimicrobial Agents and Chemotherapy·Stephan Kohlhoff, Margaret R Hammerschlag
Jan 29, 2008·Microbial Pathogenesis·Joscha GussmannThomas F Meyer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.